Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age21-45
SponsorMorten Hostrup, PhD

About this trial

This longitudinal mechanistic physiological study examines biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, with emphasis on G protein-coupled receptor kinase (GRK)-mediated pathways. Participants will receive daily oral dosing of the GRK-selective long-acting β2-agonist ATR-258 for 8 weeks. Muscle biopsies and physiological measurements will quantify GRK-, cAMP/PKA-, and β-arrestin-related signaling, fiber-type specificity, and potential receptor desensitization with repeated stimulation.

Eligibility criteria

Qualifiers

Healthy men

Age 21-45 years

BMI 25-35 kg/m²

Body fat percentage 25-40%

Disqualifiers

Regular use of or allergy to β2-agonists

Serious adverse reactions to β2-agonists

Current smoker

Regular use of medication (except OTC allergy or analgesics)

Trial design

Treatments tested in this trial

  • ATR-258

Treatment groups

10 Participants
are divided into 1 treatment group

Sponsors and collaborators

Morten Hostrup, PhD

Lead sponsor

University of Copenhagen

Sponsor institution

Atrogi AB

Collaborator

University of Copenhagen

Collaborator

Stockholm University

Collaborator